CF PHARMTECH (02652): Recommended to fully implement H-share circulation.

CF PHARMTECH (02652) announced that on November 25, 2025, the board of directors has considered and approved a proposal to convert 1.07 billion shares of non-listed domestic shares held by 20 shareholders of the company into H shares, representing approximately 26.1% of the total issued share capital of the company as of the date of this announcement. The number of non-listed domestic shares that need to be registered with the China Securities Regulatory Commission for full circulation of H shares.